Biogen (BIIB) Stock
Established biotech company treating brain and nerve conditions. Here's the price, business snapshot, and what's worth knowing about Biogen in August 2026.
Biogen Inc is a US-based biotechnology company focused on treatments for neurological and neurodegenerative conditions. Investors should know the company mixes mature revenue-generating drugs for multiple sclerosis and spinal muscular atrophy with a high-profile and sometimes volatile research pipeline. Biogen’s market capitalisation is around $21.44B, which reflects both its commercial products and the market’s view of future approvals and patent timelines. Key drivers include clinical trial results, regulatory decisions, patent expiries and partnerships; these events can move the share price substantially. There is also reputational and regulatory risk following past controversy over Alzheimer’s therapy approvals. Biogen may appeal to investors who want exposure to neuroscience-focused biotech, but suitability depends on risk tolerance, investment horizon and portfolio diversification. This is general educational information only and not personalised investment advice — consider seeking independent financial advice and review the company’s latest filings before making decisions.
Why It’s Moving
Biogen stays active after a wave of analyst target hikes kept bullish sentiment intact.
- Analysts kept Biogen in the spotlight over the past week, with Mizuho lifting its target to 241 from 221 and maintaining an Outperform stance, reinforcing the view that recent pipeline and execution trends are still supporting the name.
- A cluster of other firms also nudged targets higher in late July, including Goldman Sachs, UBS, TD Cowen, and Canaccord Genuity, which suggests the market is still leaning on a constructive long-term read despite mixed ratings.
- The consensus remains skewed toward a Buy/Moderate Buy across the Street, and that steady bullish bias is helping offset lingering skepticism from a few Hold and Market Perform calls.
Biogen stays active after a wave of analyst target hikes kept bullish sentiment intact.
- Analysts kept Biogen in the spotlight over the past week, with Mizuho lifting its target to 241 from 221 and maintaining an Outperform stance, reinforcing the view that recent pipeline and execution trends are still supporting the name.
- A cluster of other firms also nudged targets higher in late July, including Goldman Sachs, UBS, TD Cowen, and Canaccord Genuity, which suggests the market is still leaning on a constructive long-term read despite mixed ratings.
- The consensus remains skewed toward a Buy/Moderate Buy across the Street, and that steady bullish bias is helping offset lingering skepticism from a few Hold and Market Perform calls.
When is the next earnings date for BIOGEN INC (BIIB)?
Biogen’s next earnings date is expected on October 29, 2026. The report should cover Q3 2026 results. If the company follows its usual late-October schedule, that date is the most likely timing for the release and earnings call.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Biogen's stock, expecting its value to increase based on future performance.
Financial Health
Biogen is generating strong revenue and profits, demonstrating good cash flow and healthy margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring BIIB
AI-Driven Pharma Stocks | Pipeline Innovation
Novo Nordisk's partnership with OpenAI highlights a massive shift as major drugmakers integrate generative AI into their core operations. This basket captures the pharmaceutical giants optimizing their pipelines alongside the tech titans providing the underlying AI infrastructure.
Published: 15 April 2026
Explore BasketUS Pharma Reshoring | CDMOs & Supply Chain Stocks
The Trump administration is implementing sweeping 100% tariffs on imported brand-name drugs to force pharmaceutical companies into producing their medicines stateside. This aggressive policy shift creates a highly lucrative environment for US-based contract manufacturers and domestic healthcare supply chain operators as global drugmakers rush to reshore their operations.
Published: 4 April 2026
Explore BasketPharma Manufacturing | What's Next After TrumpRx
GlaxoSmithKline and Amgen are the latest pharmaceutical giants to join the TrumpRx platform, offering direct-to-consumer medications at reduced prices while committing to massive U.S. manufacturing investments. This evolving landscape creates compelling investment opportunities in domestic drug production facilities, supply chain logistics, and digital health aggregators that help patients navigate new pricing structures.
Published: 14 March 2026
Explore BasketAI Drug Discovery | Biotech Investment Opportunities
NVIDIA and Eli Lilly have launched a $1 billion AI lab to revolutionize the drug discovery process. This partnership highlights a burgeoning investment opportunity in companies at the intersection of artificial intelligence and biotechnology.
Published: 13 January 2026
Explore BasketDrug Pricing Power | Major Pharma Stocks 2025
Following plans by major drugmakers to raise prices on hundreds of medications, the pharmaceutical industry is showcasing its significant pricing power. This development highlights an investment opportunity centered on established pharmaceutical companies capable of translating market dominance into revenue growth.
Published: 2 January 2026
Explore BasketUK-US Pharma Trade Deal | Tariff-Free Market Access
A new trade deal eliminates tariffs on pharmaceuticals between the UK and the US, strengthening transatlantic trade. This creates a powerful tailwind for pharmaceutical companies in both countries, potentially boosting exports, innovation, and profitability.
Published: 2 December 2025
Explore BasketBiotech Buyout Candidates (Post-Merck Acquisition)
Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.
Published: 17 November 2025
Explore BasketM&A Activity Overview | Pharma Biotech Investments
Merck's $9.2 billion acquisition of Cidara Therapeutics aims to bolster its antiviral portfolio ahead of the Keytruda patent expiration. This strategic purchase signals a broader investment opportunity in biotech firms with advanced clinical assets, positioning them as attractive targets for major pharmaceutical companies.
Published: 15 November 2025
Explore BasketSanofi Dupixent Success Overview | Pharma Investment
Sanofi's recent profit surge, driven by its blockbuster drug Dupixent, highlights a powerful investment theme. This idea focuses on innovative pharmaceutical companies with high-growth drugs and the broader ecosystem that supports their success.
Published: 24 October 2025
Explore BasketWhy You’ll Want to Watch This Stock
Revenue and Pipeline
Biogen balances established drug sales with pipeline candidates; revenues can provide stability while trial readouts drive outlook, though results may be unpredictable.
Regulatory Catalysts
Regulatory decisions and trial outcomes are key value drivers — positive news can boost sentiment, but setbacks can quickly reverse gains.
Industry Dynamics
Competition, patent lifecycles and pricing pressure shape long-term prospects; consider diversification and risk tolerance before exposure, as biotech can be volatile.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
